Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04231643
Recruitment Status : Recruiting
First Posted : January 18, 2020
Last Update Posted : June 5, 2020
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
William Perry, University of California, San Diego

Brief Summary:
Cannabis use is associated with younger age at onset of bipolar disorder, poor outcome, and more frequent manic episodes, but the effects of cannabis on cognition are less clear. Contrary to reports among non-psychiatric patients, cannabis may improve cognition among people with bipolar disorder. Nevertheless, no study to date has systematically tested the acute effects of cannabis on cognition in bipolar disorder. Therefore, the investigators propose to determine the effects of oral cannabinoid administration on cognitive domains relevant to bipolar disorder, e.g., arousal, decision making, cognitive control, inhibition, and temporal perception (sense of timing). In addition, the investigators will evaluate different doses of the two major components of cannabis, cannabidiol and ∆9-tetrahydrocannabinol, and compare them to placebo on these neurocognitive measures. The investigators will also test the effects of acute exposure to cannabinoids on cerebrospinal levels of anandamide and homovanillic acid - markers of endocannabinoid and dopamine activity in the brain, respectively. These studies will provide information that effectively bridges the fields of addiction and general psychiatry, informing treatment development for co-morbid substance abuse and psychiatric disorders.

Condition or disease Intervention/treatment Phase
Bipolar Disorder Drug: Dronabinol Drug: Epidiolex Drug: Placebos Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 144 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Randomized, Controlled Trial of Cannabis in Bipolar Disorder Patients and Healthy Volunteers Evaluating Cognition and Endocannabinoid Levels
Estimated Study Start Date : July 1, 2020
Estimated Primary Completion Date : February 28, 2023
Estimated Study Completion Date : February 28, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Dronabinol

Arm Intervention/treatment
Experimental: Bipolar Disorder
adults with bipolar disorder
Drug: Dronabinol
one-time oral administration of 5 mg dronabinol

Drug: Epidiolex
one-time oral administration of 600 mg Epidiolex

Drug: Placebos
one-time oral administration of placebo

Active Comparator: Healthy Volunteers
adults with no psychiatric disease
Drug: Dronabinol
one-time oral administration of 5 mg dronabinol

Drug: Epidiolex
one-time oral administration of 600 mg Epidiolex

Drug: Placebos
one-time oral administration of placebo




Primary Outcome Measures :
  1. Score on Iowa Gambling Task [ Time Frame: one day ]
    This is an experimental measure and not a scale with specific anchor points. Lower scores reflect increased risk-taking

  2. Score on Progressive Ratio Test [ Time Frame: one day ]
    This is an experimental measure and not a scale with specific anchor points. Higher scores indicate increased willingness to work for a reward

  3. Scores on Probabilistic Learning Task [ Time Frame: one day ]
    This is an experimental measure and not a scale with specific anchor points. Measures decision-making strategies such as win-stay, lose-shift.

  4. Scores on Continuous Performance Task [ Time Frame: one day ]
    This is an experimental measure and not a scale with specific anchor points. Higher scores reflect better attention and ability to discriminate important information from unimportant information

  5. Percent Prepulse Inhibition (PPI) [ Time Frame: one day ]
    This is a physiological measure and not a scale with specific anchor points. Higher percent PPI reflects better sensorimotor gating

  6. motor activity in the human Behavioral Pattern Monitor [ Time Frame: one day ]
    This is an experimental measure and not a scale with specific anchor points. Subjects' behavior in an open field (a room filled with novel objects) is quantified over a 15-minute period via amount of motor activity as measured by a wearable accelerometer. Increased motor activity reflects increased tendency to engage in exploratory behavior.

  7. object interactions in the human Behavioral Pattern Monitor [ Time Frame: one day ]
    This is an experimental measure and not a scale with specific anchor points. Subjects' behavior in an open field (a room filled with novel objects) is quantified over a 15-minute period via video ratings that quantify number of interactions with novel objects. Increased object interactions reflects increased novelty-seeking behavior.

  8. cerebrospinal fluid levels of anandamide [ Time Frame: one day ]
    Reflects increased availability of the endogenous cannabinoid anandamide in the brain



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Participants will be asked about which gender they identify with
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. For subjects in BD group, DSM-5 criteria for Bipolar Disorder as determined by the Structured Clinical Interview for DSM-5 (SCID).
  2. Young Mania Rating Scale (YMRS) < 12.
  3. Infrequent cannabis use as defined by a history of cannabis use but <5 times per month [37] and no use in the past 14 days prior to experimental sessions.

Exclusion Criteria:

  1. Hamilton Depression Rating Scale (HDRS) score > 10.
  2. Suicidality. Exposure to cannabis does not lead to depression but it may be associated with suicidal thoughts and attempts. Therefore, the Center for Epidemiological Studies-Depression Scale (CES-D) subscale measuring suicidal ideation ("I wished I were dead". "I wanted to hurt myself") will be completed. Should any of these items be answered affirmatively, e.g., the subject has endorsed these items for at least 1-2 days in the last week, the subject will not be enrolled in the study.
  3. The Substance Abuse Module of the Diagnostic Interview Schedule for DSM-5 will be administered to exclude individuals with current substance use disorders.
  4. Clinically significant or unstable medical condition. Subjects will undergo a medical evaluation (H&P, toxicology screening, and for females of childbearing potential, pregnancy testing (utilizing a human chorionic gonadotropin (hCG) urine test). Individuals with significant cardiovascular disease (e.g., angina, myocardial infarction or stroke), hepatic or renal disease, uncontrolled hypertension, and chronic pulmonary disease (e.g., asthma, COPD), will be excluded. With respect to cardiovascular and pulmonary status, a clinician will screen participants with a tool developed for this purpose (Appendix 3 Cardiopulmonary Screen). Hepatic and renal disease will be evaluated with liver and renal function laboratory tests. Females who are pregnant or lactating will be excluded.
  5. Infections - evidence of skin infection at lumbar puncture site.
  6. To avoid confounding of cognitive testing, a neurological disorder such as seizures, stroke, Parkinson's disease, dementia, or a history of head injury with loss of consciousness for at least 15 minutes will be excluded.
  7. Unwilling to refrain from driving or operate heavy machinery for four hours after consuming study medication. This criterion is consistent with current expert recommendations on driving following the use of cannabis.
  8. Additionally, because the hBPM paradigm requires participants to be ambulatory, those who cannot ambulate independently (e.g., require a wheelchair) or those who have a motor disease (e.g., multiple sclerosis, cerebral palsy) will be excluded.
  9. A previous adverse reaction to cannabinoids will be cause for exclusion as will a historical diagnosis of cannabis use disorder.
  10. Positive result on Draeger 5000 test indicating recent cannabis use.
  11. Unwillingness to prevent pregnancy during the cannabinoid administration portion of the study (using birth control in female participants of child-bearing age) Acceptable methods of birth control are: oral contraceptive pills, diaphragm, condom, progestin implant, intrauterine contraceptive device, sterilization, etc.
  12. Any active opportunistic infection or malignant condition requiring acute treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04231643


Contacts
Layout table for location contacts
Contact: Nathan Wood, MA 6195436575 n2wood@ucsd.edu

Locations
Layout table for location information
United States, California
UC San Diego Medical Center Recruiting
San Diego, California, United States, 92103
Contact: Nathan Wood, MA    619-543-6575    n2wood@ucsd.edu   
Sponsors and Collaborators
University of California, San Diego
National Institute on Drug Abuse (NIDA)
Investigators
Layout table for investigator information
Principal Investigator: William Perry, PhD UCSD
Layout table for additonal information
Responsible Party: William Perry, Professor in Residence of Psychiatry, University of California, San Diego
ClinicalTrials.gov Identifier: NCT04231643    
Other Study ID Numbers: 180356
R01DA043535 ( U.S. NIH Grant/Contract )
First Posted: January 18, 2020    Key Record Dates
Last Update Posted: June 5, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by William Perry, University of California, San Diego:
cannabidiol
THC
Additional relevant MeSH terms:
Layout table for MeSH terms
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Dronabinol
Epidiolex
Hallucinogens
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Cannabinoid Receptor Agonists
Cannabinoid Receptor Modulators
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Anticonvulsants